Dr. Chelsea Elise Ray, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Sandpoint Rd, Munising, MI 49862 Phone: 906-387-4338 |
Dr. Mark Walter Olson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1504 Sand Point Road, Munising, MI 49862 Phone: 906-387-4220 Fax: 906-387-5449 |
Dr. Kurt Richard Olson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1504 Sand Point Road, Munising, MI 49862 Phone: 906-387-4220 Fax: 906-387-5449 |
David John Miller, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1500 Sandpoint Rd, Munising, MI 49862 Phone: 190-638-7411 |
Paul Walter Haduck, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Sandpoint Rd, Munising, MI 49862 Phone: 906-387-4338 Fax: 906-387-2825 |
Dr. Colin Irish, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1500 Sandpoint Rd, Munising, MI 49862 Phone: 906-387-4338 Fax: 906-387-2825 |
Michelle R Kroupa-kulik, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Sandpoint Rd, Munising, MI 49862 Phone: 906-387-4338 Fax: 906-387-2825 |
Christine M Krueger, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1504 Sandpoint Rd, Munising, MI 49862 Phone: 906-387-4220 Fax: 906-387-5449 |
News Archive
A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.
According to the Centers for Disease Control and Prevention (CDC) 1,900,000 people contract infections in hospitals, (Hospital Acquired Infections - HAIs) every year and well over 99,000 die as a result; more deaths than from AIDS, breast cancer and auto accidents combined.
NPS Board Chair Dr Janette Randall today called on the government to take the lead on a cross sectoral approach towards tackling the antibiotic-resistance crisis facing the Australian community.
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.
› Verified 6 days ago